A newly-constructed antibody-like molecule containing the gp120-binding domain of the receptor for human immunodeficiency virus blocks HIV-1 infection of T cells and monocytes. Its long plasma half-life, other antibody-like properties, and potential to block all HIV isolates, make it a good candidate for therapeutic use.
Type
research article
PubMed ID
2536900
Author(s)
Capon, D. J.
Chamow, S. M.
Mordenti, J.
Marsters, S. A.
Gregory, T.
Mitsuya, H.
Byrn, R. A.
Lucas, C.
Groopman, J. E.
Date Issued
1989
Published in
Volume
337
Issue
6207
Start page
525
End page
31
Subjects
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Note
Department of Molecular Biology, Genentech, Inc., South San Francisco, California 94080.
Editorial or Peer reviewed
REVIEWED
Written at
EPFL
EPFL units
Available on Infoscience
June 5, 2007
Use this identifier to reference this record